<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>G Paper Bulletin</title>
    <link rel="stylesheet" href="/static/G-Paper-Bulletin%20css/topic_detail%20style.css">
</head>
<body>
    <h1><a href="/g-paper-bulletin/alphabet.html">G Paper Bulletin</a>: Pegloticase Gout Treatment</h1>
    <div>
        <a href="/g-paper-bulletin/alphabet.html">Back to Topics</a><br>
    </div>
    <table border="1" cellpadding="10">
        <thead>
            <tr>
                <th>
                    <a href="/g-paper-bulletin/topic/2/paper_id.html">#
                    </a>
                </th>
                <th>
                    <a href="/g-paper-bulletin/topic/2/title.html">Title
                    </a>
                </th>
                <th>Author</th>
                <th>
                    <a href="/g-paper-bulletin/topic/2/year.html">Year
                    </a>
                </th>
                <th>
                    <a href="/g-paper-bulletin/topic/2/relevance.html">Relevance
                    </a>
                </th>
                <th>
                    <a href="/g-paper-bulletin/topic/2/innovation.html">Innovation
                    </a>
                </th>                
                <th>
                    <a href="/g-paper-bulletin/topic/2/economic.html">Economic
                    </a>
                </th>
                <th>Plot Type</th>
                <th>Image</th>
            </tr>
        </thead>
        <tbody>
            
            <tr>
                <td>1</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/5.html">Progress and challenges in PEGylated proteins downstream processing: a review of the last 8 years</a></td>
                <td>A. M. Ramos-de-la-Pe√±a</td>                
                <td>2020</td> 
                               
                <td>
                    1<br> <strong>What are the existing PEgylated drugs?<br>How to purify Pegloticase after production?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/5.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_5_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>2</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/6.html">Uricases as Therapeutic Agents to Treat Refractory Gout: Current States and Future Directions</a></td>
                <td>X. Yang</td>                
                <td>2012</td> 
                               
                <td>
                    2<br> <strong>What is a uricase?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/6.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_6_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>3</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/7.html">Therapeutic perspectives on uricases for gout</a></td>
                <td>R. P. Garay</td>                
                <td>2012</td> 
                               
                <td>
                    2<br> <strong>What was the updates on Gout therapeutics by 2012?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/7.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_7_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>4</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/8.html">New Therapies for Gout </a></td>
                <td>D. B. Crittenden</td>                
                <td>2013</td> 
                               
                <td>
                    0<br> <strong>What was the updates on Gout therapeutics by 2013?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>5</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/9.html">2010 FDA drug approvals</a></td>
                <td>A. Mullard</td>                
                <td>2011</td> 
                               
                <td>
                    0<br> <strong>What drugs were approved by the FDA in 2010?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>6</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/10.html">En Masse Excision and Curettage for Periarticular Gouty Tophi of the Hands</a></td>
                <td>M. Doscher</td>                
                <td>2022</td> 
                               
                <td>
                    0<br> <strong>What is the procedure of a tophi removal surgery?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/10.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_10_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>7</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/11.html">Treatment of tophaceous gout: When medication is not enough</a></td>
                <td>I. R. Kasper</td>                
                <td>2016</td> 
                               
                <td>
                    1<br> <strong>When drugs are not enough, how to use surgical intervention instead?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>8</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/19.html">Engineering protein-based therapeutics through structural and chemical design</a></td>
                <td>S. B. Ebrahimi</td>                
                <td>2023</td> 
                               
                <td>
                    0<br> <strong>What is the details about protein therapeutics?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/19.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_19_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>9</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/20.html">Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements</a></td>
                <td>C. J. Huang</td>                
                <td>2012</td> 
                               
                <td>
                    1<br> <strong>How to use recombinant biotech to produce Pegloticase?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>10</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/21.html">Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout</a></td>
                <td>J. S. Sundy</td>                
                <td>2007</td> 
                               
                <td>
                    0<br> <strong>What is the pharmacokinetics and pharmacodynamics of Pegloticase?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>11</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/22.html">Urate oxidase</a></td>
                <td>M. S. Hershfield</td>                
                <td>1999</td> 
                               
                <td>
                    0<br> <strong>What is the patent for Pegloticase?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                        No image available
                    
                </td>             
            </tr>
            
            <tr>
                <td>12</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/36.html">Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout</a></td>
                <td>P. E. Lipsky</td>                
                <td>2014</td> 
                               
                <td>
                    1<br> <strong>What is the details about pegloticase immunogencity?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/36.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_36_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>13</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/37.html">Emerging therapeutic options for refractory gout</a></td>
                <td>K. Jatuworapruk</td>                
                <td>2023</td> 
                               
                <td>
                    1<br> <strong>What was the updates on Gout therapeutics by 2023?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/37.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_37_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>14</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/38.html">Organic acids without a carboxylic acid functional group</a></td>
                <td>G. V. Perez</td>                
                <td>2000</td> 
                               
                <td>
                    0<br> <strong>Why is uric acid an acid?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/38.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_38_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
            
            <tr>
                <td>15</td>
                <td><a href="/g-paper-bulletin/topic/2/paper_id/39.html">State of the art in PEGylation: The great versatility achieved after forty years of research</a></td>
                <td>G. Pasut</td>                
                <td>2021</td> 
                               
                <td>
                    1<br> <strong>What is PEGylation?</strong>
                </td>
                
                <td>0</td>
                <td>0</td>
                <td>None</td>
                <td>
                    
                            <a href="/g-paper-bulletin/topic/2/paper_id/39.html" target="_blank"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_39_1.png" alt="None" class="academic-image"></a>
                    
                </td>             
            </tr>
                      
        </tbody>
    </table>

    
        </div>
            <a href="/g-paper-bulletin/alphabet.html">Back to Topics</a><br>
        <div>
    
</body>
</html>